

Cover Story
Free
By Matthew Bin Han Ong
The proportion of racial and ethnic minority patients in NCI-funded clinical trials has nearly doubled over two decades—from 14% in 1999 to 25% in 2019, according to data from NCI's National Clinical Trials Network and the NCI Community Oncology Research Program.
In Brief
Clinical Roundup


Drugs & Targets


Trending Stories
- In first NCAB director’s report, Anthony Letai focuses on centralized grant review, budget outlook
- Pazdur leaves FDA after 25-year career that shaped the agency’s oncology regulations
BIO calls for the end of “constant turmoil,” urges the administration to “right the ship” - Montefiore Einstein Director Edward Chu dies of glioblastoma at 66
- Anthony Letai pledges to ensure stability for extramural and intramural cancer science
- Vinay Prasad to CBER employees: “It is not wise for FDA to further pollute the scientific literature with papers we cannot defend”
- Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
















